Literature DB >> 33239310

Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis.

Hany M Elsheikha1, Christina M Marra2, Xing-Quan Zhu3,4.   

Abstract

Toxoplasma gondii is known to infect a considerable number of mammalian and avian species and a substantial proportion of the world's human population. The parasite has an impressive ability to disseminate within the host's body and employs various tactics to overcome the highly regulatory blood-brain barrier and reside in the brain. In healthy individuals, T. gondii infection is largely tolerated without any obvious ill effects. However, primary infection in immunosuppressed patients can result in acute cerebral or systemic disease, and reactivation of latent tissue cysts can lead to a deadly outcome. It is imperative that treatment of life-threatening toxoplasmic encephalitis is timely and effective. Several therapeutic and prophylactic regimens have been used in clinical practice. Current approaches can control infection caused by the invasive and highly proliferative tachyzoites but cannot eliminate the dormant tissue cysts. Adverse events and other limitations are associated with the standard pyrimethamine-based therapy, and effective vaccines are unavailable. In this review, the epidemiology, economic impact, pathophysiology, diagnosis, and management of cerebral toxoplasmosis are discussed, and critical areas for future research are highlighted.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Toxoplasma gondii; cerebral toxoplasmosis; diagnosis; immunocompromised patients; pathophysiology; toxoplasmic encephalitis; treatment

Year:  2020        PMID: 33239310      PMCID: PMC7690944          DOI: 10.1128/CMR.00115-19

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  227 in total

1.  Diffuse "encephalitic" cerebral toxoplasmosis in AIDS. Report of four cases.

Authors:  F Gray; R Gherardi; E Wingate; J Wingate; G Fénelon; A Gaston; A Sobel; J Poirier
Journal:  J Neurol       Date:  1989-07       Impact factor: 4.849

2.  A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis.

Authors:  Emma H Wilson; Ulrike Wille-Reece; Florence Dzierszinski; Christopher A Hunter
Journal:  J Neuroimmunol       Date:  2005-08       Impact factor: 3.478

3.  Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample.

Authors:  Nora Hamdani; Claire Daban-Huard; Mohamed Lajnef; Jean-Romain Richard; Marine Delavest; Ophélia Godin; Emmanuel Le Guen; François-Eric Vederine; Jean-Pierre Lépine; Stéphane Jamain; Josselin Houenou; Philippe Le Corvoisier; Masayuki Aoki; Helene Moins-Teisserenc; Dominique Charron; Rajagopal Krishnamoorthy; Robert Yolken; Faith Dickerson; Ryad Tamouza; Marion Leboyer
Journal:  J Affect Disord       Date:  2012-12-27       Impact factor: 4.839

Review 4.  Toxoplasma gondii: from animals to humans.

Authors:  A M Tenter; A R Heckeroth; L M Weiss
Journal:  Int J Parasitol       Date:  2000-11       Impact factor: 3.981

5.  Detection of cytokine mRNA in the brains of mice with toxoplasmic encephalitis.

Authors:  C A Hunter; C W Roberts; M Murray; J Alexander
Journal:  Parasite Immunol       Date:  1992-07       Impact factor: 2.280

Review 6.  Movement disorders with cerebral toxoplasmosis and AIDS.

Authors:  A Nath; D E Hobson; A Russell
Journal:  Mov Disord       Date:  1993       Impact factor: 10.338

7.  The Toxoplasma pseudokinase ROP5 forms complexes with ROP18 and ROP17 kinases that synergize to control acute virulence in mice.

Authors:  Ronald D Etheridge; Aditi Alaganan; Keliang Tang; Hua Jane Lou; Benjamin E Turk; L David Sibley
Journal:  Cell Host Microbe       Date:  2014-05-14       Impact factor: 21.023

8.  Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells.

Authors:  Yasuhiro Suzuki; Xisheng Wang; Benard S Jortner; Laura Payne; Yanyan Ni; Sara A Michie; Baohui Xu; Tomoya Kudo; Sara Perkins
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

9.  Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15-Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response.

Authors:  Hironori Bando; Youngae Lee; Naoya Sakaguchi; Ariel Pradipta; Ji Su Ma; Shun Tanaka; Yihong Cai; Jianfa Liu; Jilong Shen; Yoshifumi Nishikawa; Miwa Sasai; Masahiro Yamamoto
Journal:  MBio       Date:  2018-10-09       Impact factor: 7.867

10.  ICOS-deficient and ICOS YF mutant mice fail to control Toxoplasma gondii infection of the brain.

Authors:  Carleigh A O'Brien; Tajie H Harris
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

View more
  22 in total

1.  MicroRNA-155 contributes to host immunity against Toxoplasma gondii.

Authors:  Yanan Xu; Junhua Wu; Xiaoqi Yuan; Wenyuan Liu; Jiewen Pan; Binbin Xu
Journal:  Parasite       Date:  2021-12-15       Impact factor: 3.000

2.  Geospatial epidemiology of Toxoplasma gondii infection in livestock, pets, and humans in China, 1984-2020.

Authors:  Ya-Jing Su; Ze-Dong Ma; Xia Qiao; Peng-Tao Wang; Yu-Ting Kang; Ning-Ai Yang; Wei Jia; Zhi-Jun Zhao
Journal:  Parasitol Res       Date:  2022-01-06       Impact factor: 2.289

3.  Lysine crotonylation is widespread on proteins of diverse functions and localizations in Toxoplasma gondii.

Authors:  Fa-Cai Li; Lan-Bi Nie; Hany M Elsheikha; Fang-Yuan Yin; Xing-Quan Zhu
Journal:  Parasitol Res       Date:  2021-03-03       Impact factor: 2.289

4.  Cerebral toxoplasmosis associated with the use of immunosuppressive treatments.

Authors:  Ivone Melo Valadão; Ana Sofia Sequeira; Vanessa Barcelos
Journal:  Rev Soc Bras Med Trop       Date:  2022-04-08       Impact factor: 1.581

5.  Temporal transcriptomic changes in long non-coding RNAs and messenger RNAs involved in the host immune and metabolic response during Toxoplasma gondii lytic cycle.

Authors:  Sha-Sha Wang; Chun-Xue Zhou; Hany M Elsheikha; Jun-Jun He; Feng-Cai Zou; Wen-Bin Zheng; Xing-Quan Zhu; Guang-Hui Zhao
Journal:  Parasit Vectors       Date:  2022-01-10       Impact factor: 3.876

6.  Detection of Toxoplasma gondii Infections using Virus-Like Particles Displaying T. gondii ROP4 Antigen.

Authors:  Min-Ju Kim; Jie Mao; Hae-Ji Kang; Ki-Back Chu; Fu-Shi Quan
Journal:  Korean J Parasitol       Date:  2021-12-22       Impact factor: 1.341

7.  Functional Characterization of 17 Protein Serine/Threonine Phosphatases in Toxoplasma gondii Using CRISPR-Cas9 System.

Authors:  Qin-Li Liang; Lan-Bi Nie; Ting-Ting Li; Hany M Elsheikha; Li-Xiu Sun; Zhi-Wei Zhang; Dan-Yu Zhao; Xing-Quan Zhu; Jin-Lei Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-10

Review 8.  Oxidative Stress as a Possible Target in the Treatment of Toxoplasmosis: Perspectives and Ambiguities.

Authors:  Karolina Szewczyk-Golec; Marta Pawłowska; Roland Wesołowski; Marcin Wróblewski; Celestyna Mila-Kierzenkowska
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

Review 9.  Secreted Effectors Modulating Immune Responses to Toxoplasma gondii.

Authors:  Tadakimi Tomita; Rebekah B Guevara; Lamisha M Shah; Andrews Y Afrifa; Louis M Weiss
Journal:  Life (Basel)       Date:  2021-09-20

10.  Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors.

Authors:  Yu-Chao Zhu; Hany M Elsheikha; Jian-Hua Wang; Shuai Fang; Jun-Jun He; Xing-Quan Zhu; Jia Chen
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 12.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.